AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7297433
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml of magaldrate administered every three hours
Trial: 31050949
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + Laser (SRP + L)
Trial: 19631773
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no low-intensity pulsed ultrasound treatment)
Trial: 16344342
Drug: Azathioprine, up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine, up to 3 mg/kg daily, individually adjusted according to blood lymphocyte number and the occurrence of adverse events.
Trial: 9585822
Drug: Ebastine tablets
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine tablets
Trial: 7707108
Drug: CMFVP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMFVP (1 year of therapy with continuous cyclophosphamide, methotrexate, fluorouracil (5‐FU), vincristine, and prednisone)
Trial: 7707108
Drug: FAC-M (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC-M (20 weeks of therapy with four 5‐week courses of treatment with 5‐FU, doxorubicin, cyclophosphamide, and methotrexate)
Trial: 58143
Drug: B.C.G. plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B.C.G. plus 5-fluorouracil (5-F.U.)
Trial: 58143
Drug: B.C.G. alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B.C.G. alone
Trial: 27088271
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping plus paracetamol
Trial: 27088271
Drug: Paracetamol (control)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (control)
Trial: 12125505
Drug: Furosemide +
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide + albuterol (1 and 0.15 mg/kg, respectively)
Trial: 12125505
Drug: Albuterol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (0.15 mg/kg)
Trial: 26658119
Drug: Colostrum administration
RxNorm normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrum administration every 2 h for 46 h
Trial: 24884888
Drug: Internet-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioural therapy (8 modules delivered online)
Trial: 20386309
Drug: Plasma interleukin‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin‐8 levels > or =220 pg/mL
Trial: 20386309
Drug: Plasma interleukin‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin‐8 cutoff <220 pg/mL
Trial: 20386309
Drug: Plasma interleukin‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin‐8 cutoff <220 pg/mL in adults aged <40 yrs
Trial: 15974218
Drug: Bleaching gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching gel with added amorphous calcium phosphate (ACP)
Trial: 12675869
Drug: Serial slow-flow
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial slow-flow pressure (SFpr = OP/MABP at Qb of 50 mL/min)
Trial: 8908436
Drug: Norfloxacin ophthalmic
RxNorm normalized name: norfloxacin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin ophthalmic solution 0.3%
Trial: 1827418
Drug: 0.020 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.020 mg ethynilestradiol + 0.150 mg desogestrel (Mercilon)
Trial: 1827418
Drug: 0.030 mg
RxNorm normalized name: LEVONORGESTREL 0.050 mg / ETHINYL ESTRADIOL 0.030 mg ORAL TABLET, COATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.030 mg ethynilestradiol + 0.150 mg desogestrel (Marvelon)
Trial: 1827418
Drug: 0.020 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.020 mg ethynilestradiol (Mercilon)
Trial: 1827418
Drug: 0.030 mg
RxNorm normalized name: LEVONORGESTREL 0.050 mg / ETHINYL ESTRADIOL 0.030 mg ORAL TABLET, COATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.030 mg ethynilestradiol (Marvelon)
Trial: 6345174
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose melphalan/prednisone (MP)
Trial: 6345174
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose melphalan (M)
Trial: 30608426
Drug: aPDT (antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aPDT (antimicrobial photodynamic therapy)
Trial: 17605095
Drug: AF Suppression
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF Suppression algorithm ON (treatment group)
Trial: 9719037
Drug: Sugar-free, urea-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-free, urea-containing chewing gum (20 mg urea/piece), 5 pieces/day
Trial: 26386786
Drug: Varenicline (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1.0 mg twice daily)
Trial: 17211114
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no exercise treatment during the research period)
Trial: 12899796
Drug: Suppository treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository treatment for bleeding due to hemorrhoid
Trial: 12899796
Drug: Suppository treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository treatment for prolapse of hemorrhoid
Trial: 1310497
Drug: etanidazole (ETA)
RxNorm normalized name: Tinidazole
DrugBank: Etanidazole (DB12736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: etanidazole (ETA) unmodified (2 g/m2, 3 times weekly for 17 doses)
Trial: 1310497
Drug: etanidazole (ETA)
RxNorm normalized name: Tinidazole
DrugBank: Etanidazole (DB12736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: etanidazole (ETA) individualized dose modification
Trial: 29018084
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (0.5 mg/kg)
Trial: 20940337
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin (5 U)
Trial: 20940337
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (10 U)
Trial: 20940337
Drug: Inhaled Technosphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Technosphere insulin (25, 50, and 100 U)
Trial: 15118650
Drug: Prenatal zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal zinc supplementation (25 mg zinc)
Trial: 7884791
Drug: Moexipril monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moexipril monotherapy (7.5, 15, or 30 mg once daily)
Trial: 7884791
Drug: Moexipril combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moexipril combined with hydrochlorothiazide (15-30 mg daily with 12.5 mg hydrochlorothiazide)
Trial: 30706520
Drug: Active strategy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active strategy for the diagnosis and anticoagulant treatment of pulmonary embolism (PE)
Trial: 30706520
Drug: Active strategy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active strategy for the diagnosis and anticoagulant treatment of PE
Trial: 18000659
Drug: Erlotinib with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib with ketoconazole (CYP3A4 inhibitor)
Trial: 17010056
Drug: Selective estrogen
RxNorm normalized name: Selective estrogen receptor modulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective estrogen receptor modifiers (tamoxifen, raloxifene)
Trial: 11128246
Drug: Gabapentin monotherapy
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin monotherapy after discontinuation of carbamazepine (CBZ)
Trial: 11128246
Drug: Other antiepileptic
RxNorm normalized name: Other antiepileptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antiepileptic medications
Trial: 1493661
Drug: Propionyl-L-carnitine (PLC)
RxNorm normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine (PLC) 1 g b.i.d
Trial: 2859304
Drug: Rapidly eliminated
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rapidly eliminated hypnotics (triazolam, midazolam, lormetazepam)
Trial: 2859304
Drug: Slowly eliminated
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slowly eliminated hypnotics (flurazepam, quazepam)
Trial: 24472084
Drug: Compound betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound betamethasone 7 mg intramuscular injection (i.m.) once
Trial: 24472084
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 75 mg twice a day for 7 days
Trial: 17907112
Drug: No GIK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No GIK infusion (Control)
Trial: 2025478
Drug: Ketanserin 10
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 10 mg i.v. followed by an infusion of 0.075 mg kg‐1 h‐1
Trial: 6894644
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (20 minutes of isometric exercises)
Trial: 30257898
Drug: Ceftaroline disk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftaroline disk diffusion with 30-μg disks
Trial: 30257898
Drug: Ceftaroline MIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftaroline MIC of 2 μg/ml
Trial: 30257898
Drug: Ceftaroline MIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftaroline MIC of 1 μg/ml
Trial: 30257898
Drug: Ceftaroline MIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftaroline MIC of ≥4 μg/ml
Trial: 25729196
Drug: Spinal decompression
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal decompression therapy (SDTG, n=15)
Trial: 25729196
Drug: General traction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General traction therapy (GTTG, n=15)
Trial: 18679072
Drug: PEG‐IFN monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN monotherapy (n=64)
Trial: 16531440
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid 10 mg kg(‐1) i.v. just before tourniquet deflation and 3 h later
Trial: 16531440
Drug: epsilon‐aminocaproic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epsilon‐aminocaproic acid 100 mg kg(‐1) before tourniquet deflation followed by continuous perfusion (1 g h(‐1)) during 3 h
Trial: 11966791
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg twice a day for 10 days
Trial: 11966791
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg twice a day for 14 days
Trial: 162923
Drug: Adenine arabinoside
RxNorm normalized name: Adenine
DrugBank: Adenine (DB00173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenine arabinoside (20 mg/kg of body weight, intravenously every 24 hr for seven days in an 8-hr infusion)
Trial: 7362724
Drug: Suxamethonium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1.0 mg kg‐1
Trial: 26867157
Drug: Panitumumab added
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab added to docetaxel-based chemotherapy
Trial: 26867157
Drug: Docetaxel-based chemotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel-based chemotherapy alone
Trial: 17992451
Drug: UVB monotherapy
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UVB monotherapy
Trial: 12010156
Drug: Non-submerged ITI
RxNorm normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-submerged ITI implants
Trial: 12010156
Drug: First 498
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First 498 implants after at least five years of functional loading
Trial: 12010156
Drug: 12 mm
RxNorm normalized name: ReliOn Pen Needle 29g 12 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mm long implants
Trial: 12010156
Drug: 8 mm
RxNorm normalized name: potassium 8 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mm long implants
Trial: 12010156
Drug: Implants supporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants supporting maxillary overdentures retained by Dolder bars
Trial: 7821124
Drug: Loxiglumide (CCK-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (CCK-receptor antagonist)
Trial: 1695053
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMW heparin) given once daily
Trial: 76748
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (E.C.T.)
Trial: 20037706
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone hexacetonide combined with 15 mCi Samarium(153)‐particulate hydroxyapatite (Sm/TH group)
Trial: 20037706
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone hexacetonide alone (TH group)
Trial: 17696821
Drug: Biologic drugs
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic drugs
Trial: 15151687
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education programme (yearly 1-h instruction)
Trial: 12359855
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid at 4 mg
Trial: 12359855
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid at 8/4 mg
Trial: 12359855
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid at 4 mg and 8/4 mg
Trial: 1155918
Drug: Gentamicin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (2 mg/kg)
Trial: 26265109
Drug: Warming blanket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming blanket plus prewarmed intravenous (i.v.) infusion
Trial: 20189775
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg every 12h for 5 days
Trial: 20189775
Drug: Oseltamivir 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 225 mg every 12h for 5 days
Trial: 20189775
Drug: Oseltamivir 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 450 mg every 12h for 5 days
Trial: 10812285
Drug: THC (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (0 mg)
Trial: 8684686
Drug: r-HuEPO (4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-HuEPO (4000 IU/ml, subcutaneous treatment on alternate days)
Trial: 1904892
Drug: Open label
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label drug titration (nonrandomized patients)
Trial: 1904892
Drug: Double-blind placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind placebo therapy (control group)
Trial: 29171848
Drug: (+)-epicatechin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-epicatechin (30 mg per day for 7 days)
Trial: 29171848
Drug: (+)-epicatechin (incremental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-epicatechin (incremental doses of 10, 30 or 100 mg)
Trial: 29171848
Drug: (+)-epicatechin (0.003,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-epicatechin (0.003, 0.01, 0.03, 0.1 and 0.3 mg kg-1 day-1 for 2 weeks)
Trial: 29171848
Drug: +catechin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +catechin (0.1 mg kg-1 day-1)
Trial: 29231495
Drug: Shallow needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shallow needling therapy (at sites 0.2 to 0.3 cun lateral to the acupoints, no qi arrival required)
Trial: 29231495
Drug: Shallow needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shallow needling therapy
Trial: 25588685
Drug: AEQ >0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEQ >0.4 ng/L/s in patients with paroxysmal AF
Trial: 16636540
Drug: Plasma NT-proBNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma NT-proBNP >162.2 pmol/l
Trial: 16636540
Drug: Plasma NT-proBNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma NT-proBNP levels in the highest quartile (> or =162.2 pmol/l)
Trial: 12559795
Drug: IM high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM high dose hepatitis B virus (HBV) vaccine
Trial: 12559795
Drug: IM standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM standard dose HBV vaccine plus granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Trial: 12559795
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose HBV vaccine plus GM‐CSF
Trial: 3318723
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg methylprednisolone infusion
Trial: 3318723
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g methylprednisolone infusion
Trial: 3318723
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (unspecified alternative therapy)
Trial: 26153378
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin three times a day for 7 days postoperatively
Trial: 26153378
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin plus topical ciprofloxacin drops (4 drops three times a day for 3 days)
Trial: 1611835
Drug: Ponalrestat (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponalrestat (600 mg day‐1)
Trial: 6365809
Drug: sfericase (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sfericase (2 tablets, 3 times/day, total daily dose of 6 tablets)
Trial: 29332024
Drug: Apotel (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apotel (1 g in 200 cc normal saline for 20 min)
Trial: 29332024
Drug: Remifentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.5 μg/kg/min)
Trial: 23480201
Drug: Basic oral
RxNorm normalized name: sodium phosphate, dibasic Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic oral hygiene instruction (Control)
Trial: 20640546
Drug: Power Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Power Training (PT) and Hormone Replacement Therapy (HRT)
Trial: 16286743
Drug: Lichtena plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lichtena plus 25 microg/g triamcinolone acetonide (TACA)
Trial: 11898768
Drug: Vitamins C
RxNorm normalized name: MULTIVITAMINS CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins C and E (200mg vitamin C and 50mg vitamin E, both twice per day for 4 weeks)
Trial: 11898768
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (Bismuth chelate, tetracycline, and metronidazole for 2 weeks)
Trial: 11898768
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Vitamins C and E + Triple therapy)
Trial: 7599850
Drug: Methacholine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine (0.03 to 256 mg/ml)
Trial: 1450684
Drug: Yeast-derived recombinant
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast-derived recombinant vaccine 1
Trial: 1450684
Drug: Yeast-derived recombinant
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast-derived recombinant vaccine 2
Trial: 6364880
Drug: control (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (5% ethanol solution)
Trial: 29396000
Drug: Cycling of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycling of antibiotics (third-generation or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems)
Trial: 29396000
Drug: Mixing strategy
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixing strategy (changing antibiotic to an alternative class for each consecutive patient)